Size:
0.09 MB
(PDF)
Rating:
Boehringer Ingelheim and DxS sign agreement for a companion diagnostic test to identify EGFR mutations in patients with lung cancer
Boehringer Ingelheim
Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
Manchester, UK and Ingelheim, Germany - 29 May 2009
DxS, a personalised medicine company, and Boehringer Ingelheim, a global group of pharmaceutical companies, headquartered in Germany, have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992* to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.
*BIBW 2992 is an investigational compound. Its safety and efficacy has not yet been fully established.
Items: 10
Source for healthcare professionals: www.inoncology.com
* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.
© 2012 Boehringer Ingelheim GmbH. All rights reserved.
|
Terms of use
|
Imprint
Boehringer Ingelheim on
